Strategic partnerships Molecular Partners leverages collaborations with leading pharmaceutical companies and is expanding capabilities in Radio-DARPin therapeutics through a recent partnership with Eckert & Ziegler, presenting a channel for co-development, manufacturing access, and accelerate clinical timelines.

Clinical-stage focus As a clinical-stage biotech with multiple preclinical and clinical programs, primarily in oncology, there is a continuous need for CROs, contract manufacturing, and regulatory consulting partners to support ongoing trials and future late-stage development.

Radiopharma opportunity The company is actively developing Radio-DARPin platforms and is engaging with radiopharmaceutical events and suppliers, signaling demand for specialized isotopes, imaging agents, and manufacturing partners to scale dosing and clinical studies.

Geographic reach With offices in Zurich and Concord, MA, and a multinational investor and partner footprint, there are opportunities to pursue cross-border regulatory services, regional clinical trial operations, and market-entry support in both Europe and North America.

Financial readiness Current revenue and modest funding levels combined with ongoing clinical activities indicate appetite for strategic investors, grant opportunities, and financing partnerships to support expansion, manufacturing scale-up, and additional P1-P3 trials.